McN-4612
McN-4612 is a noradrenaline-preferring serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) developed by McNeil Laboratories in the 1980s.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
McN-4612 is a noradrenaline-preferring serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) developed by McNeil Laboratories in the 1980s.
Self-administration studies
Although McN-4612 was never publicly taken by humans, the self-administration by rats is reported in the literature.
Synthesis
A number of methods are available to synthesizing these agents in the appendant literature. The first scheme relies on 2,2-diphenylethylamine, which itself is the product of the reduction of diphenylacetonitrile. However, the 2-phenylpyrrolidine route is also attractive.
Recently, an enantiomerically selective method was reported using this method of synthesis. It is worth noting that this compound is itself made from 4-chlorobutyronitrile.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1349604261 under CC BY-SA 4.0; modifications have been made.